Drugs / Nadroparin Calcium
last change Aug 2026 re-read 9 days ago

Nadroparin Calcium

Other / unclassified targets SERPINC1 via activation

Developed for
venous thromboembolism · cirrhosis of liver · portal vein thrombosis · pulmonary embolism · end stage renal failure · hepatocellular carcinoma · inherited thrombophilia · ischemic stroke
+3 more · acquired aneurysmal subarachnoid hemorrhage · brain ischemia · neoplasm
Investigated by
Shanghai Zhongshan Hospital · Eastern Hepatobiliary Surgery Hospital · Qilu Hospital of Shandong University · Suzanne C. Cannegieter, MD PhD · ZonMw: The Netherlands Organisation for Health Research and Development · Air Force Military Medical University, China
+21 more · Alice Ho Miu Ling Nethersole Hospital · Beijing Chao Yang Hospital · Canadian Institutes of Health Research (CIHR) · Clinique Saint Pierre Ottignies · GlaxoSmithKline · IRCCS Azienda Ospedaliero-Universitaria di Bologna · Italfarmaco · Liaocheng People's Hospital · Marc Blondon · Medical University of Vienna · Red Cross Hospital Beverwijk · Rijnstate Hospital · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai Public Health Clinical Center · Shanghai Pudong New Area Gongli Hospital · Shengqing Li · ShuGuang Hospital · Taian City Central Hospital · University Hospital, Martin · University of Calgary · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Trials 22

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/32 trials · 1 met primary
Phase 2/3 NCT00881088 Apr 2009 → Apr 2013 pulmonary embolism, venous thromboembolism Red Cross Hospital Beverwijk Unknown Met primary
Phase 2/3 NCT00827554 Dec 2008 → Aug 2011 hepatocellular carcinoma Eastern Hepatobiliary Surgery Hospital Completed No outcome recorded
Phase 36 trials · 1 met primary
Phase 3 NCT07140211 Oct 2025 → Aug 2030 expected puerperal disorder, venous thromboembolism Marc Blondon Recruiting No outcome recorded
Phase 3 NCT06494878 Apr 2025 → Aug 2030 expected venous thromboembolism University of Calgary Not yet recruiting No outcome recorded
Phase 3 NCT01980849 Nov 2013 → Nov 2016 lung cancer Shengqing Li Unknown No outcome recorded
Phase 3 NCT01019655 Jan 2010 → Jan 2012 inherited thrombophilia Medical University of Vienna Unknown No outcome recorded
Phase 3 NCT00312013 May 2006 → Jul 2009 venous thromboembolism GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00951574 Oct 2003 → May 2007 metastatic malignant neoplasm Italfarmaco Completed Met primary
Phase 49 trials
Phase 4 NCT04976543 Feb 2020 → Dec 2021 cirrhosis of liver, hemorrhagic disease, portal vein thrombosis Qilu Hospital of Shandong University Completed No outcome recorded
Phase 4 NCT04173429 Jan 2017 → Jan 2020 cirrhosis of liver, portal vein thrombosis Qilu Hospital of Shandong University Completed No outcome recorded
Phase 4 NCT02957877 Mar 2016 → May 2018 end stage renal failure Alice Ho Miu Ling Nethersole Hospital Unknown No outcome recorded
Phase 4 NCT02630095 Dec 2015 → Sep 2018 cirrhosis of liver, portal vein thrombosis Shanghai Zhongshan Hospital Unknown No outcome recorded
Phase 4 NCT04982055 Apr 2015 → Dec 2020 — Clinique Saint Pierre Ottignies Completed No outcome recorded
Phase 4 NCT02398357 Mar 2015 → Aug 2017 cirrhosis of liver, portal vein thrombosis Shanghai Zhongshan Hospital Unknown No outcome recorded
Phase 4 NCT01862978 May 2013 → May 2015 ischemic stroke University Hospital, Martin Unknown No outcome recorded
Phase 4 NCT02295150 Mar 2013 → Jun 2015 morbid obesity, venous thromboembolism Rijnstate Hospital Unknown No outcome recorded
Phase 4 NCT00796692 Jun 2002 → Feb 2006 pulmonary embolism, thrombotic disease, venous thromboembolism Beijing Chao Yang Hospital Completed No outcome recorded
Phase not applicable5 trials · 2 missed
— NCT01542723 May 2012 → Jul 2016 pulmonary embolism, venous thromboembolism Suzanne C. Cannegieter, MD PhD Completed Missed primary
— NCT01542762 Mar 2012 → Jul 2016 pulmonary embolism, venous thromboembolism Suzanne C. Cannegieter, MD PhD Completed Missed primary
— NCT01267305 Jan 2011 → Apr 2013 lung neoplasm, neoplasm of esophagus, venous thromboembolism Shanghai Zhongshan Hospital Completed No outcome recorded
— NCT00669721 Mar → Jun 2008 kidney failure IRCCS Azienda Ospedaliero-Universitaria di Bologna Unknown No outcome recorded
— NCT02526303 ? → Feb 2017 cirrhosis of liver, portal vein thrombosis Air Force Military Medical University, China Withdrawn No outcome recorded
Comparator or background therapy14 trials
Phase 1/2 NCT03282643 Comparator Feb 2016 → Jun 2018 neoplasm Capital Medical University Completed Met primary
Phase 2 NCT04507178 Comparator Feb 2022 → Aug 2026 overdue acquired aneurysmal subarachnoid hemorrhage, brain ischemia Academic Medical Center - University of Amsterdam Recruiting No outcome recorded
Phase 3 NCT04067505 Comparator May 2020 → Dec 2024 May-Thurner syndrome Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 3 NCT04066764 Comparator May 2020 → Oct 2024 venous thromboembolism Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 3 NCT01431456 Comparator Sep 2013 → Oct 2014 venous thromboembolism Martini Hospital Groningen Completed No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 37 sources stand behind the page.

FieldValueCited text
Known as Nadroparin Calcium “Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous” NCT03671174 ↗
7

“Nadroparin Calcium and Warfarin” NCT02526303 ↗

NCT00951574 ↗

NCT02630095 ↗

NCT01019655 ↗

NCT04976543 ↗

NCT01267305 ↗

NCT04173429 ↗

Known as CY 216 ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗
Known as Fraxiparin ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗
Known as Fraxiparina ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗
Known as Fraxiparine “LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg)...” NCT00796692 ↗
3

“subcutaneous injection of LMWH, Fraxiparine (n = 23) (0.4 ml, 3800 IU/day) for 2 days” PMID 30903459 ↗ May 2019

“Fraxiparine” NCT02238444 ↗

NCT02987946 ↗

Known as Nadroparin “LMWHs like Nadroparin and Dalteparin are no experimental pharmaceuticals; both have been registered in the Netherlands for these indications since 1989.” NCT01542762 ↗
25

“50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks” NCT00827554 ↗

“Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days.” NCT01542723 ↗

“nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis” NCT00669721 ↗

“Dalteparin, Enoxaparin, Nadroparin, Tinzaparin” NCT06494878 ↗

“nadroparin 3800-5700IU o.d.” NCT07140211 ↗

“nadroparin” NCT01164046 ↗

“Nadroparin” NCT01531829 ↗

NCT00843492 ↗

NCT04067505 ↗

NCT06319131 ↗

Show 15 more sources

Known as Nadroparina calcica ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗
Known as Nadroparine calcique ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗
Known as Seleparina ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗
Known as Ultraparina ChEMBL registry synonym — accepted as the source's own label CHEMBL2109204 ↗
Action Activate “Antithrombin-III activator” CHEMBL2109204 ↗
Modality Other / unclassified “nadroparin is a low molecular weight heparin” NCT00286273 ↗
Route Subcutaneous “subcutaneous for 2 weeks” NCT00312013 ↗
Target SERPINC1 “Antithrombin-III activator” CHEMBL2109204 ↗